Precision oncology, also known as precision medicine in cancer care, tailors treatments to the individual genetic profile of a patient's tumor. This approach uses biomarker testing—such as next-generation sequencing (NGS) and companion diagnostics—to identify specific molecular alterations driving cancer growth, enabling targeted therapies that improve outcomes while minimizing side effects. In Europe, where cancer is the second leading cause of death accounting for 23% of all fatalities and projected to claim 1.23 million lives in the EU alone by 2026, the need for equitable access to these innovations has never been more urgent. Recent projections indicate 3.2 million new cases and 1.6 million deaths by 2040, with economic losses reaching €1.3 trillion in productivity from 2018 to 2040.

On March 6, 2026, the European Federation of Pharmaceutical Industries and Associations (EFPIA) Oncology Platform released a landmark white paper titled "Advancing Precision Oncology Treatment and Testing Across Europe: An Evidence-Based Roadmap for Healthcare System Stakeholders to Improve Cancer Care." Launched at a high-level event in Toledo, Spain, in partnership with Farmaindustria, the document addresses persistent disparities in biomarker testing and targeted treatments across Member States. It provides a practical toolkit drawn from 15 case studies and promising practices, urging coordinated action amid EU initiatives like Europe's Beating Cancer Plan and the European Health Data Space (EHDS).

🔬 The Growing Burden of Cancer and Promise of Precision Oncology

Cancer incidence is rising due to aging populations and lifestyle factors, with age-standardized mortality rates declining slightly (114.1 per 100,000 for males and 74.7 for females in 2026) but absolute numbers climbing. Precision oncology counters this by matching therapies to tumor genetics—e.g., EGFR inhibitors for lung cancer or HER2-targeted drugs for breast cancer—potentially boosting survival rates by 20-50% in responsive cases. Yet, access remains fragmented: a 2022 ESMO survey found single biomarker testing turnaround times averaging 12.6 days but NGS under 10% in many countries, with quality highest in Western/Northern Europe (>90% labs in quality schemes).

Universities play a pivotal role, leading research into novel biomarkers and training oncologists. Institutions like the German Cancer Research Centre (DKFZ) and Catalonia's bioinformatics networks exemplify academic-industry collaborations driving PO forward.

Challenges Highlighted in the EFPIA White Paper

The white paper identifies three core barriers via 'system archetypes':

• Awareness gaps: 70% of metastatic breast cancer patients unaware of biomarkers like ESR1; professionals lack training; payers undervalue long-term savings.
• Infrastructure and workforce shortages: Fragmented labs, insufficient molecular tumor boards (MTBs), data silos, and bioinformatics skills deficits hinder timely testing.
• Funding misalignments: Delays in reimbursing test-treatment pairs (e.g., 203 days median from EMA approval to funding in some cases), out-of-pocket costs, and siloed budgets.

These create a 'two-tier' system, exacerbating inequities in rural or underserved areas.

Photo by Markus Winkler on Unsplash

🛠️ The White Paper's Implementation Toolkit and Archetypes

EFPIA's roadmap diagnoses systems using archetypes (e.g., 'pilot-heavy fragmentation' or 'reimbursement lag') and offers sequenced actions:

It leverages EU tools like the Joint Action on Personalised Cancer Medicine (JA PCM) for scaling.

Spotlight on 15 Case Studies: Best Practices from Europe and Beyond

The white paper showcases proven models:

• France (INCa): Expanded oncogenetics consultations from 12,696 (2003) to 94,855 (2022) via networks and campaigns.
• Netherlands: Hartwig's OncoAct WGS for 1,200 patients yielded 71% new options; reimbursed in targeted settings.
• Germany (DKTK): Links uni clinics for ctDNA roll-out; trained 1,000+ professionals.
• Ireland (NCIS): National system standardizes data for 130,000 chemo cycles/year.
• Italy (Emilia-Romagna): Regional MTB/DBO for NGS tracking.
• Spain (Catalonia POP): 23,135 NGS tests; 25% treatment changes.
• Sweden (GMS): Nationwide NGS/WGS coverage.
• Belgium: Fast-track NGS reimbursement (23,000 tests/2023).
• And more from Finland, England, etc.

These demonstrate scalable solutions adaptable to local contexts. Download the full white paper for details.

Universities Driving PO Innovation and Training

European universities are central to PO progress. The PreciseOnco consortium (2026, €14.9M EU funding) unites Philips, uni hospitals, and research centers for immuno-oncology biomarkers. Initiatives like PRIME-ROSE (Netherlands) merge data for precision care, while Horizon Europe 2026 calls boost cancer missions. Institutions train via MTBs and bioinformatics programs, addressing workforce gaps. For aspiring researchers, explore research jobs in oncology across Europe.

Photo by Artyom Korshunov on Unsplash

Stakeholder Perspectives: Patients, Clinicians, and Policymakers

Patients via Cancer Patients Europe highlight awareness needs (70% mBC unaware). Clinicians praise MTBs for 20-30% actionable insights. Payers note cost savings (e.g., NGS €1,150/test vs. ineffective chemo). The white paper calls for patient reps in HTA, aligning views for holistic reform.

Future Outlook: Europe's Path to PO Leadership

By 2028, full EBCP integration could standardize NGS, cut disparities, and save billions. Challenges like data privacy persist, but EU levers (EHDS, MFF) offer momentum. Universities must expand training; check faculty positions in precision medicine. For career advice, visit higher-ed career advice.

In summary, the EFPIA white paper is a call to action. Implementing its roadmap promises transformative cancer care. Stay informed via Europe higher ed news.